To the Editor, Breast cancer is the most frequently diagnosed cancer and the leading cause of cancer death in women. In general, patients with early-stage breast cancer undergo primary surgery (lumpectomy or mastectomy) to the breast and regional nodes with or without radiation therapy (RT). Among women with operable breast cancer, randomized trials have demonstrated equivalent disease-free and overall survival between mastectomy and breast-conserving therapy [1] [2] [3] [4] . Breast reconstruction is an option for patients following a unilateral or bilateral mastectomy. Modern breast reconstruction began in 1964 with the introduction of the silicone breast implant. Implants can help restore the breast to normal appearance. Common complications of breast reconstruction using implants and expanders include capsular contracture and implant failure. Silicone lymphadenopathy involving axillary lymph nodes is an uncommon complication after breast reconstruction surgery. We presented 3 patients with silicone lymphadenopathy in this paper. In this article we presented three cases of silicone implant induced lymphadenopathy. The common characteristics of the 3 cases were the reactive lymphadenopathies after silicone implant approches. Biopsies were performed from 3 patients and no malignancy was detected. Breast conserving surgery (BCT) and mastectomy reconstruction is appropriate for most women with early stage breast cancer. Oncoplastic surgery approaches are frequently used today for early stage breast cancer patients after local treatment.
Reconstructive breast surgery can be performed using tissue flap or implant-based techniques. During the last four decades, silicone has become one of the most extensively utilized materials for this purpose. There are numerous complications of silicone materials including local and systemic granulomatous inflammatory reactions affecting breast tissue, lymph nodes, joint capsules, heart, liver, and kidneys. In a retrospective review of over 18,000 procedures, the incidence of noninfectious complications was 10.3 percent after mastectomy plus implant, 17.4 percent after mastectomy plus flap and 11.7 percent for mastectomy plus implant and flap 5 . Silicone implant-induced lymphadenopathy is an uncommon side effect [6] [7] [8] [9] . The diagnosis is made by physical examination and radiological examinations. The distinction of malign lymphadenopathy is very important for these patients.
In conclusion, silicone implant-induced lymphadenopathy is a rare complications of siliconecontaining prostheses and it can be confused for malignancy in patients with breast implant.
